Ex-New York congressman pleads guilty in insider trading case

Published 10/01/2019, 04:47 PM
© Reuters. Chris Collins, former U.S. Representative for New York's 27th congressional district departs after pleading guilty at Federal Court in New York City, New York

By Brendan Pierson

NEW YORK (Reuters) - Chris Collins, a former U.S. Congressman from New York state who was known as an early backer of President Donald Trump, pleaded guilty on Tuesday to taking part in an insider trading scheme.

Collins, 69, entered his plea to charges of conspiracy and making false statements to investigators before U.S. District Judge Vernon Broderick in Manhattan the day after he resigned his seat in the U.S. House of Representatives.

He faces a maximum of five years in prison for each of the two charges when he is sentenced on Jan. 17, though prosecutors have agreed as part of a plea deal that a reasonable sentence would be a total of less than five years.

Collins had represented New York's 27th Congressional District, which includes areas surrounding Buffalo and Rochester in western New York. He narrowly won re-election last November, three months after he was criminally charged.

The criminal case arises from Collins' role as a board member and 16.8% stakeholder of Australian biotechnology company Innate Immunotherapeutics Ltd.

Collins said in court Tuesday that in June 2017, during a congressional picnic on the White House lawn, he learned in an email from Innate's chief executive that the company's experimental multiple sclerosis drug, MIS416, had failed in a clinical trial.

Collins admitted that he immediately called his son, Cameron Collins, to tell him the news, allowing him to sell his Innate shares and avoid losses when it became public. Chris Collins said he was in "a very emotional state" when he made the call because he was upset the drug had failed.

"When I did these things, I knew they were illegal and improper," he said. "The actions I took are anything but those a model citizen would take."

The congressman did not trade his own Innate stock, which lost millions of dollars in value. Prosecutors have said he was "virtually precluded" from trading in part because he already faced a congressional ethics probe over Innate.

However, they said, Cameron Collins went on to tip his fiancée, Lauren Zarsky; her parents, Dorothy and Stephen Zarsky; and a friend. Stephen Zarsky went on to tip off additional unnamed people, the prosecutors said.

In all, prosecutors said, the people who received the tips were able to avoid a total of more than $768,000 in losses when Innate's share price plunged 92% after news of the drug's failure became public.

Cameron Collins, 26, and Stephen Zarsky, 67, have been charged in the case and are scheduled to plead guilty on Thursday, court records show.

© Reuters. Chris Collins, former U.S. Representative for New York's 27th congressional district departs after pleading guilty at Federal Court in New York City, New York

Lauren and Dorothy Zarsky were not criminally charged, but agreed to surrender the money they made selling Innate stock to the Securities and Exchange Commission under a civil settlement without admitting wrongdoing.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.